摘要
目的探讨添加脑栓通胶囊治疗阿司匹林抵抗的急性脑梗死患者的临床价值。方法将94例有阿司匹林抵抗现象的急性脑梗死患者分为对照组(45例)与观察组(49例),对照组患者仅接受常规治疗,观察组患者在对照组治疗基础上添加使用脑栓通12周,在治疗结束后对比分析两组患者的血小板聚集率及临床疗效。结果①治疗前两组患者血小板聚集率相比差异无统计学意义(P>0.05);治疗12周后,观察组血小板聚集率显著低于对照组(P<0.05)。②治疗前,两组患者NHISS评分、BI评分相比差异无统计学意义(P>0.05)。治疗12周后,观察组NHISS评分显著低于对照组(P<0.05),BI评分显著高于对照组(P<0.05)。③观察组观察期内复发率显著低于对照组(P<0.05),两组患者脑出血发生率差异无统计学意义(P>0.05)。结论脑栓通添加治疗可改善急性脑梗死患者的阿司匹林抵抗现象,降低血小板聚集率,同时改善患者临床预后和降低疾病复发率。
Objective Explore clinical value of naoshuantong treatment in patients who are aspirin resistance with cerebral infarction. Methods 94 patients were divided into control group （45 cases） and observation group （49 cases）, control group patients received only conventional therapy, observation group of patients based on the control group treatment and combined use naoshuantong 12 weeks. At the end of the treatment, comparative analysis of two groups of patients. Result ①before the treatment, the platelet aggregation rate two groups of patients was no statistically signiifcant difference （P＆gt;0.05）, after 12 weeks treatment, the observation platelet aggregation rate was signiifcantly lower than the control group （P＆lt;0.05）.②before the treatment, two groups of patients, NHISS score compared with BI score was no statistically signiifcant difference （P＆gt;0.05）. 12 weeks after treatment, the observation group NHISS score was signiifcantly lower than the control group （P＆lt;0.05）, BI score was signiifcantly higher than the control group （P＆lt;0.05）.③Observation group follow-up recurrence rate was signiifcantly lower than the control group （P＆lt;0.05）. Conclusion Naoshuantong treatment in patients with cerebral infarction can reduce aspirin resistance and platelet aggregation rate, improve clinical prognosis and decrease recurrence rate.
出处
《中国医药指南》
2014年第5期19-20,共2页
Guide of China Medicine
关键词
脑栓通
阿司匹林抵抗
脑梗死
Naoshuantong
Aspirin resistance
Cerebral infarction
